{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+4&page=30",
    "query": {
      "intervention": "cohort 4",
      "page": 30
    },
    "page_size": 10
  },
  "pagination": {
    "page": 30,
    "page_size": 10,
    "total_count": 3785,
    "total_pages": 379,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+4&page=31&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+4&page=29&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T03:33:29.411Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07763015",
      "title": "Study of Resmetirom in Children and Adolescents With MASH",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "MASH",
        "MASH - Metabolic Dysfunction-Associated Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "Resmetirom",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Madrigal Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 61,
      "start_date": "2026-08-01",
      "completion_date": "2029-07",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-11-19T03:33:29.411Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07763015"
    },
    {
      "nct_id": "NCT07424547",
      "title": "Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer",
        "Solid Tumor Cancer",
        "Advanced Metastatic Cancer",
        "Prostate",
        "Small Cell Lung Cancer",
        "Ovarian Cancer",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "SYS6043",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Conjupro Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 386,
      "start_date": "2026-03-03",
      "completion_date": "2030-04",
      "has_results": false,
      "last_update_posted_date": "2026-04-07",
      "last_synced_at": "2026-11-19T03:33:29.411Z",
      "location_count": 5,
      "location_summary": "Plantation, Florida • Austin, Texas • San Antonio, Texas + 1 more",
      "locations": [
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07424547"
    },
    {
      "nct_id": "NCT01680835",
      "title": "EverFlex Post Approval Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Peripheral Arterial Disease",
        "Lower Extremity Arterial Disease"
      ],
      "interventions": [
        {
          "name": "EverFlex™ Self-Expanding Peripheral Stent System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Medtronic Endovascular",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 108,
      "start_date": "2013-01-14",
      "completion_date": "2019-02-04",
      "has_results": true,
      "last_update_posted_date": "2019-12-26",
      "last_synced_at": "2026-11-19T03:33:29.411Z",
      "location_count": 23,
      "location_summary": "Phoenix, Arizona • Modesto, California • Sacramento, California + 20 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Modesto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01680835"
    },
    {
      "nct_id": "NCT03478930",
      "title": "An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Nasal Polyps",
        "Chronic Rhinosinusitis"
      ],
      "interventions": [
        {
          "name": "Omalizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 249,
      "start_date": "2018-05-09",
      "completion_date": "2020-03-16",
      "has_results": true,
      "last_update_posted_date": "2022-04-04",
      "last_synced_at": "2026-11-19T03:33:29.411Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        },
        {
          "city": "Stockton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03478930"
    },
    {
      "nct_id": "NCT02738775",
      "title": "Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ublituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "TG Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 49,
      "start_date": "2016-05-27",
      "completion_date": "2018-08-13",
      "has_results": true,
      "last_update_posted_date": "2021-07-15",
      "last_synced_at": "2026-11-19T03:33:29.411Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Pasadena, California • Torrance, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02738775"
    },
    {
      "nct_id": "NCT02288481",
      "title": "A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "TBA-354",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Global Alliance for TB Drug Development",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "19 Years to 50 Years"
      },
      "enrollment_count": 48,
      "start_date": "2015-01",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2019-09-06",
      "last_synced_at": "2026-11-19T03:33:29.411Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02288481"
    },
    {
      "nct_id": "NCT01147965",
      "title": "QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Lung Cancer",
        "Breast Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Ad5 CEA Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "NantCell, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "21 Years to 75 Years"
      },
      "enrollment_count": 43,
      "start_date": "2010-07-16",
      "completion_date": "2017-05-31",
      "has_results": true,
      "last_update_posted_date": "2025-11-25",
      "last_synced_at": "2026-11-19T03:33:29.411Z",
      "location_count": 2,
      "location_summary": "Durham, North Carolina • Spokane, Washington",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01147965"
    },
    {
      "nct_id": "NCT01714739",
      "title": "A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "CANCER,NOS"
      ],
      "interventions": [
        {
          "name": "Lirilumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 337,
      "start_date": "2012-10-07",
      "completion_date": "2019-12-13",
      "has_results": true,
      "last_update_posted_date": "2023-02-02",
      "last_synced_at": "2026-11-19T03:33:29.411Z",
      "location_count": 16,
      "location_summary": "San Francisco, California • Ocala, Florida • Chicago, Illinois + 11 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Lutherville",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01714739"
    },
    {
      "nct_id": "NCT03477175",
      "title": "Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "E7080",
          "type": "DRUG"
        },
        {
          "name": "Comparator Drug",
          "type": "DRUG"
        },
        {
          "name": "Comparator Drug: Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2018-08-16",
      "completion_date": "2023-12-21",
      "has_results": true,
      "last_update_posted_date": "2025-01-07",
      "last_synced_at": "2026-11-19T03:33:29.411Z",
      "location_count": 3,
      "location_summary": "Torrance, California • Chicago, Illinois • Detroit, Michigan",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03477175"
    },
    {
      "nct_id": "NCT01672775",
      "title": "A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Renal Cell",
        "Renal Cell Carcinoma of Papillary Histology",
        "Renal Cell Carcinoma With Clear Cell Histology",
        "Renal Cell Carcinoma With Non-Clear Cell Histology"
      ],
      "interventions": [
        {
          "name": "AGS-16C3F",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agensys, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2012-07-18",
      "completion_date": "2017-02-21",
      "has_results": false,
      "last_update_posted_date": "2024-11-01",
      "last_synced_at": "2026-11-19T03:33:29.411Z",
      "location_count": 5,
      "location_summary": "Ann Arbor, Michigan • Detroit, Michigan • Buffalo, New York + 2 more",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01672775"
    }
  ]
}